CITI/CALL/VERTEX PHARMACEUTICALS/480/0.1/19.12.24 | Delayed Deutsche Boerse AG 01:46:07 03/06/2024 pm IST | ||
| 3.06 EUR | +9.68% |
|
| 1 month | +146.90% | ||
| 3 months | +2.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 3.06 | +9.68% |
| 31/24/31 | 2.79 | +18.72% |
| 30/24/30 | 2.35 | -4.47% |
| 29/24/29 | 2.46 | -5.02% |
| 28/24/28 | 2.59 | -20.06% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 01:46 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KH8AXN |
| ISIN | DE000KH8AXN6 |
| Date issued | 24/07/2023 |
| Strike | 480 $ |
| Maturity | 19/12/2024 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 1.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.99 € |
|---|---|
| Lowest since issue | 0.92 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
